Menu
Search
|

Menu

Close
X

Beigene Ltd BGNE.OQ (NASDAQ Stock Exchange Global Select Market)

163.19 USD
-- (--)
As of Jul 16
chart
Previous Close 163.19
Open --
Volume --
3m Avg Volume 117,681
Today’s High --
Today’s Low --
52 Week High 220.09
52 Week Low 65.68
Shares Outstanding (mil) 4.14
Market Capitalization (mil) 8,929.05
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
33
FY17
238
FY16
1
FY15
9
EPS (USD)
FY18
-0.156
FY17
-0.183
FY16
-0.274
FY15
-0.139
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
32.96
8.04
Price to Book (MRQ)
vs sector
6.53
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
12.92
17.43
LT Debt to Equity (MRQ)
vs sector
12.21
13.25
Return on Investment (TTM)
vs sector
-15.45
13.23
Return on Equity (TTM)
vs sector
-17.48
15.27

EXECUTIVE LEADERSHIP

John Oyler
Chairman of the Board, Chief Executive Officer, Founder, Since 2010
Salary: $97,664.00
Bonus: $1,272,070.00
Xiaobin Wu
President, Since 2018
Salary: --
Bonus: --
Howard Liang
Chief Financial Officer and Chief Strategy Officer, Since 2015
Salary: --
Bonus: --
Wendy Yan
Senior Vice President, Head of Regulatory Affairs, Since 2014
Salary: $68,510.00
Bonus: --
Jason Yang
Senior Vice President, Head of Clinical Development, Since 2014
Salary: $116,129.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

C/O Mourant Ozannes Corporate Se
94 Solaris Avenue, Camana Bay
GRAND CAYMAN     KY1-1108

Phone: +1345.9494123

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

SPONSORED STORIES